

Online Resource 4 – Electronic Supplementary Material to:

Use and Outcomes of Cost-Effectiveness Analyses and Additional Considerations in
Pharmaceutical Reimbursement in the Netherlands

Journal

Pharmacoeconomics

Authors

Diederik Brokkelkamp¹

Vivian Reckers-Droog¹

Lonneke Timmers^{1,2}

Pieter van Baal¹

Affiliations


- ^{1.} Erasmus School of Health Policy & Management (ESHPM), Erasmus University
Rotterdam, Rotterdam, The Netherlands
- ^{2.} National Health Care Institute (ZIN), Diemen, The Netherlands

Corresponding author

Diederik Brokkelkamp

Email: brokkelkamp@eshpm.eur.nl

Fig. S4.1 Differences between ICERs of pharmaceutical-indications with greater incremental costs and effects and their relevant reference values



Note. Dashed line at €0 indicates point where ICERs (as reported by ZIN) do not deviate from the relevant reference values. Negative differences (i.e., below €0) indicate cost-effective pharmaceutical-indications, positive differences (i.e., above €0) indicate cost-ineffective pharmaceutical-indications.

Fig. S4.2 Number of negotiation recommendations per year 2015–2024




Table S4.3 Mean and median ICERs of pharmaceutical-indications with greater incremental costs and effects by reference value (n = 65), including means based on the lower and upper bounds of the most plausible ICER range

Reference value	€20,000 per QALY	€50,000 per QALY	€80,000 per QALY	Pooled
Mean ICER reported by ZIN*	€97,300	€81,400	€278,900	€207,700
(Mean difference from ICER manufacturers)	(+ €18,900)	(+ €9,800)	(+ €51,400)	(+ €37,000)
Mean ICER reported by ZIN (lower bound)*	€81,300	€70,200	€270,300	€197,600
Mean ICER reported by ZIN (upper bound)*	€113,400	€92,500	€288,800	€218,600
Median ICER reported by ZIN	€56,100	€46,300	€160,200	€113,000
Mean % deviation from reference value†	+ 386.5%	+ 62.7%	+ 248.6%	+ 214.9%
Median % deviation from reference value†	+ 180.4%	- 7.3%	+ 100.2%	+ 88.8%
Count	7	17	41	65
Number of indications with adaptations to ICER by ZIN	4/7	8/17	18/41	30/65
Number of indications below the reference value	3/7	9/17	11/41	23/65

Note. *In 13 of the 65 indications reported here, ZIN identified the most plausible ICER as a range rather than a point estimate. The 'lower bound' and 'upper bound' rows recalculate the mean using the lower and upper bound of the range for these 13 indications; all other indications use the original point estimate.

†Negative deviations indicate ICERs below reference values, whereas positive deviations indicate ICERs above reference values.

ICERs are rounded to the nearest hundred.

Pooled estimates combine ICERs assessed against different reference values and should be interpreted descriptively only.

CEA = cost-effectiveness analysis; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; ZIN = National Health Care Institute.